enzastaurin + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Hodgkin Lymphoma
Conditions
Non Hodgkin Lymphoma
Trial Timeline
Jun 1, 2006 → Jul 1, 2013
NCT ID
NCT00332202About enzastaurin + placebo
enzastaurin + placebo is a phase 3 stage product being developed by Eli Lilly for Non Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00332202. Target conditions include Non Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00414960 | Phase 2 | Completed |
| NCT00415363 | Phase 2 | Completed |
| NCT00332202 | Phase 3 | Completed |
Competing Products
20 competing products in Non Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Tirabrutinib | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| ONO-7018 + ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY4152199 - IV | Eli Lilly | Phase 1 | 33 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |